<unk> tomy was considered to be the 1st line treatment option for<unk><unk> <unk><unk>  (SMZL) but recent studies have shown that rituximab is equally effective if not better treatment option in terms of overall survival.<unk> tomy is still performed but mainly in patients with splenomegaly without lymphadenopathy having low surgical risk or in those who are refractory to rituximab therapy.
Splenic marginal zone lymphoma surgery
Mantle cell lymphoma surgery
Diffuse large B cell lymphoma surgery
Anaplastic large cell lymphoma surgery
Thymic carcinoma surgery
Burkitt's lymphoma surgery
Extranodal NK-T-cell lymphoma surgery
Myeloproliferative neoplasm surgery